Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
Acetylcholine receptor (AChR) antibodies are specific proteins that can be found in the bloodstream of individuals diagnosed with myasthenia gravis (MG), a rare neuromuscular disorder characterized by muscle weakness and fatigue. Myasthenia gravis can manifest in two primary forms: ocular myasthenia gravis, which primarily affects the eye muscles, leading to symptoms such as drooping eyelids and double vision, and generalized myasthenia gravis, which can involve weakness in various muscle groups, including those responsible for neck movement, chewing, swallowing, speaking, and even breathing. It is important to note that approximately 15% of individuals with MG may only experience ocular symptoms. The presence of AChR antibodies disrupts the normal communication between nerves and muscles by interfering with acetylcholine, the neurotransmitter responsible for transmitting signals at the neuromuscular junction. Specifically, binding antibodies can activate complement pathways, leading to the destruction of the neuromuscular junction and a reduction in the number of available acetylcholine receptors. To diagnose the presence of these antibodies, a venous blood sample is collected, and a quantitative radioimmunoassay is performed. A positive result for AChR binding antibodies, defined as a level greater than 0.4 nmol/L, can confirm the diagnosis of myasthenia gravis in symptomatic patients. However, it is noteworthy that 10%-15% of individuals with MG may not test positive for AChR antibodies and may require further testing for other antibodies, such as muscle-specific kinase (MuSK) antibodies. Binding antibodies are particularly prevalent in patients with generalized myasthenia gravis, making this test a critical component in the diagnostic process.
© Copyright 2026 Coding Ahead. All rights reserved.
The acetylcholine receptor (AChR) binding antibody test is indicated for the diagnosis of myasthenia gravis (MG), particularly in patients presenting with symptoms consistent with this neuromuscular disorder. The following conditions and symptoms warrant the performance of this test:
The procedure for testing AChR binding antibodies involves several key steps to ensure accurate results. First, a healthcare professional will collect a sample of venous blood from the patient. This is typically done using a standard venipuncture technique, where a needle is inserted into a vein, usually in the arm, to draw blood into a collection tube. Once the blood sample is obtained, it is sent to a laboratory for analysis. In the laboratory, a quantitative radioimmunoassay is performed to measure the levels of AChR binding antibodies present in the blood sample. This assay utilizes specific reagents that bind to the AChR antibodies, allowing for the quantification of these proteins. The results of the test are then interpreted, with a binding antibody level greater than 0.4 nmol/L being considered positive for the presence of AChR antibodies. This positive result can help confirm the diagnosis of myasthenia gravis in patients who exhibit relevant symptoms.
After the blood sample has been collected for the AChR binding antibody test, there are generally no specific post-procedure care requirements for the patient. Patients may resume their normal activities immediately following the blood draw. However, it is advisable for patients to monitor the puncture site for any signs of excessive bleeding, swelling, or infection. The results of the test will typically be communicated to the patient by their healthcare provider, who will discuss the implications of the findings and any necessary follow-up actions or additional testing that may be required based on the results. In cases where AChR antibodies are not detected, further testing for other antibodies, such as muscle-specific kinase (MuSK) antibodies, may be indicated to aid in the diagnosis of myasthenia gravis.
| Short Descr | ACETYLCHOLN RCPTR BNDNG ANTB | Medium Descr | ACETYLCHOLINE RECEPTOR BINDING ANTIBODY | Long Descr | Acetylcholine receptor (AChR); binding antibody | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2024-01-01 | Added | Code Added. |
Get instant expert-level medical coding assistance.